To better your understanding of non-clinical career options and/or facilitate your physician career change, today we introduce you to Carrolee Barlow, MD, PhD. Dr. Barlow joined BrainCells, Inc. (BCI), a biopharmaceutical company focused on the development of breakthrough small molecule therapeutics for diseases of the central nervous system (CNS), in August 2004. She is the Chief Scientific Officer of the company.
Prior to joining BCI, Dr. Barlow was the Director of Molecular Neuroscience and the Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories. At Merck, Dr. Barlow directed the neuroscience biology and screening efforts at the San Diego site and served as the therapeutic area head for the global exploratory, licensing and full-phase efforts in the area of stroke and neurodegeneration. Dr. Barlow joined Merck in 2002. Prior to joining Merck, she held a faculty position in the Laboratory of Genetics at the Salk Institute for Biological Studies in La Jolla, California, where she maintained an adjunct appointment. At the Salk Institute, her research laboratory focused on developing and studying animal models of human neurological disease.
Dr. Barlow completed her M.D. training at the University of Utah followed by a residency at The New York Hospital, Cornell Medical Center in Internal Medicine. After completing her residency training, she obtained a Ph.D. in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stockholm, Sweden. After completion of her Ph.D. research, she returned to the United States and joined the National Institutes of Health where she completed medical subspecialty training in the field of endocrinology and a post-doctoral fellowship in neurogenetics at the National Human Genome Research Institute.
This biography and more information about Dr. Barlow and BCI can be found at the company website.
